Spherical nucleic acid

Exicure to Present at Upcoming TIDES USA Oligonucleotide & Peptide Therapeutics Conference

Retrieved on: 
Monday, May 9, 2022
Biotechnology, Genetics, Health, Company, Drug development, Treatment, Spherical nucleic acid, Neuroscience, Peripheral neuropathy, Hair loss, Lists of diseases, NASDAQ, Fine chemical, Video game

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.

Key Points: 
  • Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022.
  • Virtual posters will go live at the start of the conference and will be available to conference attendees for 2 weeks.
  • Exicure will add the poster to its website after the conference.
  • Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss.

Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress

Retrieved on: 
Friday, March 25, 2022
Biotechnology, General Health, Genetics, Health, Administration, SNA, Company, Ipsen, Private Securities Litigation Reform Act, Mission statement, NASDAQ, Therapy, Patent, Investment, Forward-looking statement, Lists of diseases, Clinical trial, Spherical nucleic acid, Neuroscience, Research, HD, AbbVie, Neurodegeneration, Achievement, U.S. Securities and Exchange Commission, Pain, G&A, Safety, SCN9A, Time, Architecture, Angelman syndrome, COVID-19, Intellectual property, Hair loss, Attention, R, Research and development, Corporation, Patient, Security (finance), Pharmaceutical industry, Birth control, Fine chemical

Corporate highlights for 2021 include:

Key Points: 
  • Corporate highlights for 2021 include:
    Entered into an exclusive collaboration targeting rare neurodegenerative disorders with Ipsen in July 2021 to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntingtons disease (HD) and Angelman syndrome (AS).
  • Completed a strategic review in fourth quarter of 2021, which resulted in a restructuring and pipeline focus on preclinical programs targeting SCN9A in pain and partnered programs.
  • Completed a $11.5 million registered direct offering in December 2021.
  • Exicure anticipates results from initial in vivo animal studies by year-end 2022 with goal of therapeutic candidate selection in the second half of 2023.

Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors

Retrieved on: 
Friday, February 4, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Private Securities Litigation Reform Act, Safety, Forward-looking statement, Patient, Intellectual property, Audit, NASDAQ, Institutional review board, Audit committee, Professional Football Compensation Committee, Lists of diseases, SNA, Â, Patent, Technology, Board of directors, Board, COVID-19, SCN9A, U.S. Securities and Exchange Commission, AbbVie, Neurology, Special, Company, Financial compensation, Science, Architecture, Spherical nucleic acid, Attention, Security (finance), Therapy, Compensation, Chairperson, Management, Risk management

The Board has appointed Matthias Schroff, Ph.D., Exicures current Chief Scientific Officer, to succeed Mr. Bock effective February 4, 2022.

Key Points: 
  • The Board has appointed Matthias Schroff, Ph.D., Exicures current Chief Scientific Officer, to succeed Mr. Bock effective February 4, 2022.
  • Additionally, Dr. Schroff was appointed as a member of the Companys Board of Directors to fill the vacancy resulting from Mr. Bocks resignation from the Board.
  • Timothy P. Walbert, who currently serves as Exicures Chair of the Board, and Bosun Hau, a Board member and Compensation Committee Chair, have each tendered their resignations to step down from the Board, effective February 4, 2022.
  • to succeed Mr. Walbert as Chair of the Board and to serve on the Compensation Committee of the Board of Directors to fill the vacancy on the Compensation Committee resulting from Mr. Haus resignation from the Board.

Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, December 14, 2021
Biotechnology, Genetics, Health, Forward-looking statement, U.S. Securities and Exchange Commission, Spherical nucleic acid, Form, Intellectual property, Company, Prospectus, Private Securities Litigation Reform Act, Sale, COVID-19, Neurology, NASDAQ, SEC, LLC, SEC filing, 3rd Floor, Safety, Patient, Lists of diseases, Park Avenue, Therapy, Attention, Security (finance), Patent, Architecture, Technology, SNA, Pharmaceutical industry, Nasdaq

The closing of the offering is expected to occur on or about December 16, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about December 16, 2021, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from this offering are expected to be approximately $11.5 million, before deducting the placement agents fees and other offering expenses payable by the Company.
  • The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
  • All statements in this press release other than statements of historical fact could be deemed forward looking including, but not limited to, statements regarding the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of net proceeds from the registered direct offering.

Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus

Retrieved on: 
Friday, December 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Intellectual property, Board, Human resources, Angelman syndrome, U.S. Securities and Exchange Commission, Time, Technology, Neuropathic pain, Therapy, SNA, Knowledge, Program, Â, Midcap, COVID-19, Forward-looking statement, Security (finance), SVB, Patient, Leadership, Lists of diseases, Audit committee, NASDAQ, Company, Wind, Spherical nucleic acid, Research, Safety, SCN9A, Patent, Review, SEC, Director, Audit, Neurology, Private Securities Litigation Reform Act, AbbVie, Workforce, Architecture, Pain, Silicon Valley Bank, Pharmaceutical industry, Medical device, Management

Exicure, Inc. (NASDAQ: XCUR) announced the results of its previously disclosed independent internal investigation and a number of strategic actions aimed to reduce cash spend and prioritize the Companys therapeutic pipeline.

Key Points: 
  • Exicure, Inc. (NASDAQ: XCUR) announced the results of its previously disclosed independent internal investigation and a number of strategic actions aimed to reduce cash spend and prioritize the Companys therapeutic pipeline.
  • The results of the investigation are summarized below.
  • Dr. David Giljohann, the Companys former Chief Executive Officer, has resigned from the Board and will serve as Chief Technology Officer through January 31, 2022.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress

Retrieved on: 
Friday, November 19, 2021
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Tissue, FA, Private Securities Litigation Reform Act, Patient, State Administrative Expenses, Research and development, Research, MCC, Review, Safety, Security (finance), Cell, Audit committee, Technology, Audit, Industry, FXN, CSCC, Time, Income, Company, Inflammation, Forward-looking statement, Partnership, HD, Mission statement, Clinical trial, Spherical nucleic acid, AbbVie, U.S. Securities and Exchange Commission, Therapy, COVID-19, Lists of diseases, Intellectual property, Angelman syndrome, DNA, SNA, R, Patent, Neurology, RNA, Board, Architecture, Administration, ORR, NASDAQ, Growth, Pharmaceutical industry, Cryptocurrency

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported financial results for the quarter ended September 30, 2021 and provided an update on corporate progress.

Key Points: 
  • Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported financial results for the quarter ended September 30, 2021 and provided an update on corporate progress.
  • Research and Development (R&D) Expenses: R&D expenses were $16.5 million for the quarter ended September 30, 2021, compared to $9.1 million for the quarter ended September 30, 2020.
  • General and Administrative Expenses: General and administrative expenses were $2.9 million for the quarter ended September 30, 2021, compared to $2.4 million for the quarter ended September 30, 2020.
  • For further financial information for the period ending September 30, 2021, please refer to the financial statements appearing at the end of this release.

Exicure Files Form 12b-25

Retrieved on: 
Monday, November 15, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Audit committee, Neurology, Private Securities Litigation Reform Act, Audit, U.S. Securities and Exchange Commission, Security (finance), NASDAQ, Technology, Lists of diseases, Calendar, Architecture, Forward-looking statement, Spherical nucleic acid, Board, Company, Therapy, SEC, Inflammation, Review, SNA, FA, Patient, Cryptocurrency

Exicure, Inc. (NASDAQ: XCUR) today announced that it has filed a Form 12b-25 with the U.S. Securities and Exchange Commission (the SEC) in connection with its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the Form 10-Q).

Key Points: 
  • Exicure, Inc. (NASDAQ: XCUR) today announced that it has filed a Form 12b-25 with the U.S. Securities and Exchange Commission (the SEC) in connection with its Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the Form 10-Q).
  • Exicure, Inc. (the Company) is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the Q3 2021 10-Q) with the SEC within the prescribed time period without unreasonable effort or expense.
  • Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology.
  • Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).

Exicure to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, October 28, 2021
Biotechnology, Genetics, Health, Oncology, Spherical nucleic acid, Neurology, Inflammation, Technology, Architecture, SNA, CET, Patient, NASDAQ, FA, Mouse, Lists of diseases, ICM, Therapy, Pharmaceutical industry

Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.

Key Points: 
  • Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.
  • Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).
  • Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.
  • Exicure is based in Chicago, IL and in Cambridge, MA.

Exicure to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, October 7, 2021
Oncology, Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, NASDAQ, FA, Spherical nucleic acid, SNA, Inflammation, Architecture, Lists of diseases, Neurology, Therapy, Patient, Technology, Pharmaceutical industry

Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.

Key Points: 
  • Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics.
  • Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).
  • Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.
  • Exicure is based in Chicago, IL and in Cambridge, MA.

Exicure to Present at the Chardan Virtual 5th Annual Genetic Medicines Conference

Retrieved on: 
Monday, October 4, 2021
Health, Infectious Diseases, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FA, Inflammation, Therapy, Conference, NASDAQ, Webcast, Patient, Lists of diseases, Neurology, Technology, Architecture, Spherical nucleic acid, SNA, Pharmaceutical industry

Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.

Key Points: 
  • Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.
  • Replays of the webcast will be available on Exicures website for 30 days following the webcast.
  • Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology.
  • Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA).